Zumutor Biologics Announces US$7.3 Million Pre-Series B Financing Amid Growing Clinical Momentum
Bangalore, June 16, 2026: Zumutor Biologics today announced the successful closing of a US$7.3 million Pre-Series B financing round, with participation from existing investors Accel and Bharat Innovation Fund, alongside new investors Premji Invest, Ashish Kacholia, and Raj Dandu (Dandu Family Office).
The financing positions the company to complete the ongoing US FDA Phase 1 clinical study of ZM008, both as a monotherapy and in combination regimens, while enabling the initiation of Phase 1B expansion cohorts and global Phase 2 studies, including in India.
Zumutor’s lead program, ZM008, is a first-in-class NK cell checkpoint designed to unlock the power of innate immunity against cancer. The company has observed encouraging early clinical signals in selected difficult-to-treat tumour types, reinforcing the potential of its differentiated immuno-oncology platform.
“The encouraging early clinical signals reinforce our belief in the potential of ZM008 and motivate us to continue advancing innovative therapies for patients with significant unmet medical needs,” said Kavitha Iyer Rodrigues, Founder and CEO of Zumutor Biologics.
“Early clinical data from the ongoing Phase 1 study of ZM008 highlight the differentiated potential of novel NK checkpoint therapy for solid tumors. Building on these findings, we are expanding into dose expansion cohorts and combination studies across multiple tumor types,” said Maloy Ghosh, Chief Scientific Officer, Zumutor Biologics.
Zumutor extends its sincere gratitude to its investors for their continued trust and partnership. The company also acknowledges the extraordinary contributions of its teams across India and the United States, as well as the patients and families participating in its clinical studies, principal investigators, and advisors whose dedication and commitment have made this progress possible.
The financing reflects continued confidence in Zumutor’s scientific platform, clinical strategy, and long-term vision of developing transformative immunotherapies for patients with cancer.
With this financing, Zumutor is well positioned to advance its clinical programs by initiating Phase 1B expansion cohorts and global Phase 2 studies, accelerating the translation of innovative science into meaningful outcomes for cancer patients worldwide.
#Zumutor #Immunotherapy #Oncology #NKCells #Biotech #ClinicalTrials #CancerResearch #InnateImmunity #Innovation #Healthcare
